Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children

Journal of Investigational Allergology and Clinical Immunology

Volumn 24, Issue 3, 2014, Pages 154-161

  Corzo, J L ^a   Carrillo, T ^b   Pedemonte, C ^c   Plaza Martin A M ^d   Martin Hurtado, S ^e   Dige, E ^f   Calderon, Moises A ^g  

^a HOSPITAL MATERNO INFANTIL   (Spain)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c Hospital de Nens   (Spain)

^d HOSPITAL SANT JOAN DE DÉU   (Spain)

^e Department of Biological Investigation   (Spain)

^f ALK ABELLÓ   (Denmark)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

House dust mite; Phase I; Placebo controlled; Sublingual immunotherapy; Sublingual immunotherapy tablet

Indexed keywords

IMMUNOGLOBULIN E;

ADULT; AGED; ARTICLE; ASTHMA; BIOLOGICAL ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; HOUSE DUST ALLERGY; HUMAN; IMMUNOLOGY; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MOUTH EXAMINATION; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUBLINGUAL IMMUNOTHERAPY; TABLET;

ADOLESCENT; ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERSENSITIVITY; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PYROGLYPHIDAE; SUBLINGUAL IMMUNOTHERAPY; TABLETS;

EID: 84903374313     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24:758-64.
2. Dahl R, Andersen P, Chivato T, Valovirta E, de Monchy J. National prevalence of respiratory allergic disorders. Respir Med 2004; 98:398-403.
3. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van WC, Agache I, it-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, Van CP, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Nnesi-Maesano I, Bateman ED, Ben KA, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska- Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 Suppl 86:8-160.
4. Marogna M, Massolo A, Berra D, Zanon P, Chiodini E, Canonica GW, Passalacqua G. The type of sensitizing allergen can affect the evolution of respiratory allergy. Allergy 2006; 61:1209-15.
5. Linneberg A, Henrik Nielsen N, Frolund L, Madsen F, Dirksen A, Jorgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 2002; 57:1048-52.
6. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA).Available from: http://www.ginaasthma.org/. 2010.
7. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, van Wijk RG, Ohta K, Zuberbier T, Schunemann HJ. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126:466-76.
8. EMEA. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006[Final]. 2008.
9. Durham SR, Emminger W, Kapp A, de Monchy JGR, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25.
10. World Medical Association. The Declaration of Helsinki: Ethical Principles for Medical Research Involving Human SubjectsFirst adopted in 1964 (Helsinki, Finland) and revised in 1975 (Tokyo, Japan), 1983 (Venice, Italy), 1989 (Hong Kong), 1996 (Somerset-West, South Africa) and 2000 (Edinburgh, Scotland). Note of clarification, 2002 (Washington).1996.
11. National Institutes of health. WHO/GINA workshop report: Global Strategy for asthma management and prevention. NIH publication No 02-3659, 1-192. 2002.
12. ICH. ICH Harmonised Tripartite Guideline Topic E2A. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.1994.
13. Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-73.
14. Malling H-J, Lund L, Ipsen H, Poulsen LK. Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets. Journal Investig Allergol Clin Immunol 2006; 16:162-8.
15. Ibanez MD, Kaiser F, Knecht R, Armentia A, Schopfer H, Tholstrup B, Bufe A. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007; 18:516-22.
16. Andre C, Vatrinet C, Galvain S, Carat F, Sicard H. Safety of sublingual-swallow immunotherapy in children and adults. Int Arch Allergy Immunol 2000; 121:229-34.
17. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011; 127:64-71.
18. Nettis E, Giordano D, Pannofino A, Ferrannini A, Tursi A. Safety of inhalant allergen immunotherapy with mass unitsstandardized extracts. Clin Exp Allergy 2002; 32:1745-9.
19. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-90.
20. Calderon M, Essendrop M. Specific immunotherapy with high dose SO standardized grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 2006; 16:338-44.
21. Shamji MH, James LK, Durham SR. Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011; 31:311-23.
22. Durham SR, Emminger W, Kapp A, Colombo G, De Monchy JG, Rak S, Scadding GK, Andersen JS, Riis B, Dahl R. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-8.
23. Shamji MH, Ljorring C, Francis JN, Calderon A, Larche M, Kimber I, Frew AJ, Ipsen H, Lund K, Wurtzen PA, Durham SR. Functional rather than immunoreactive levels of IgG(4) correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67:217-26.
24. Mosbech H, Deckelmann R, de BF, Pastorello EA, Trebas-Pietras E, Andres LP, Malcus I, Ljorring C, Canonica GW. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebocontrolled trial. J Allergy Clin Immunol. 2014. DOI: 10.1016/j. jaci.2014.03.019